Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
VCYT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.61 - $47.32
Previous CloseN/A
Volume253.49K
Average Volume (3M)1.95M
Market Cap
$2.48B
Enterprise Value$1.85B
Total Cash (Recent Filing)$320.72M
Total Debt (Recent Filing)$50.65M
Price to Earnings (P/E)94.7
Beta1.62
Next Earnings
Nov 11, 2025EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.44
Shares Outstanding78,671,585
10 Day Avg. Volume965,422
30 Day Avg. Volume1,952,028
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue3.86
Enterprise Value/Gross Profit5.73
Enterprise Value/Ebitda31.47
Forecast
1Y Price Target
$37.75Price Target Upside16.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Business StrategyVCYT has no debt, $321M of cash, is cash flow positive, and profitable.
Financial PerformanceTotal 2Q revenues of $130.16M were solidly ahead of consensus $121M, and management initiated guidance of $496-504M while also raising testing revenues guide.
Product DevelopmentThe company's pipeline is expected to unlock more value with several catalysts and launches over the next 12 to 18 months.
Bears Say
Market CompetitionThe rapidly evolving competitive / IP dynamics in the MRD market bear watching.
Regulatory ChallengesNasal Swab reimbursement is also unlikely to fall in place until 2028+ at the earliest in light of the NIGHTINGALE enrollment expected to complete in 3Q25.
Veracyte News
VCYT FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $22.61 and its highest was $47.32 in the past 12 months.
What is Veracyte’s market cap?
Veracyte’s market cap is $2.48B.
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is Nov 11, 2025 which is in 64 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on Aug 06, 2025. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.264 by $0.176.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is 0.32.
How many shares outstanding does Veracyte have?
Veracyte has 78,671,585 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of $0.44 in its last earnings report, beating expectations of $0.264. Following the earnings report the stock price went up 15.478%.
Which hedge fund is a major shareholder of Veracyte?
Currently, no hedge funds are holding shares in VCYT
Veracyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.75 (16.40% Upside)
$37.75 (16.40% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 969.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.93%
12-Months-Change
Fundamentals
Return on Equity
2.24%
Trailing 12-Months
Asset Growth
8.89%
Trailing 12-Months
Company Description
Veracyte
Veracyte, Inc. is a genomic diagnostics company that focuses on improving patient outcomes through the development and commercialization of diagnostic tests for patients with cancer and other diseases. The company operates primarily in the healthcare sector, offering innovative solutions that enhance the accuracy of diagnoses and help physicians make informed treatment decisions. Veracyte's core products include its proprietary genomic tests, such as the Afirma Genomic Sequencing Classifier for thyroid cancer and the Percepta Genomic Sequencing Classifier for lung cancer, which are designed to reduce unnecessary surgeries and improve patient management.
VCYT Company Deck
VCYT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reveals a positive outlook for Veracyte, with strong revenue growth driven by Decipher and Afirma tests, successful launch of new products, and an impressive cash position. However, there are challenges such as a decline in product revenue and the impact of the Veracyte SAS sale on future margins.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$37.75
▲(16.40% Upside)
Technical Analysis
Ownership Overview
1.47% Insiders
35.69% Mutual Funds
1.14% Other Institutional Investors
35.46% Public Companies and
Individual Investors